Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-41BB mAb, Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid Leukemia (AML)

Trial Profile

An Open-label Phase IB/II Multi-Arm Study of OX40 Agonist Monoclonal Antibody (mAb), Anti-41BB mAb, Anti-PDL1 mAb, Smoothened Inhibitor, Anti-CD33 mAb, and Azacitidine as Single-Agents and/or Combinations for the Treatment of Patients With Acute Myeloid Leukemia (AML)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Aug 2018

At a glance

  • Drugs Avelumab (Primary) ; Azacitidine (Primary) ; Gemtuzumab ozogamicin (Primary) ; Glasdegib (Primary) ; PF 4518600 (Primary) ; Utomilumab (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2018 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
    • 08 Jan 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top